1 Min Read
** The drugmaker’s shares up 28 pct at $3.88
** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.